Argenx SE stock (NL0010832176): focus on Vyvgart growth after latest earnings update
Argenx SE remains in focus following its latest quarterly results, with particular attention on the growth of its lead therapy, Vyvgart, for generalized myasthenia gravis and other IgG-mediated conditions. The company highlighted ongoing revenue growth, a strong cash position, and continued investment in its clinical pipeline, transitioning from a pure R&D entity to one with a growing commercial footprint. While still investing heavily in R&D, Argenx is expanding Vyvgart's reach through broader geographic rollout and development of subcutaneous formulations, with ongoing trials to expand its application to other IgG-mediated indications.
MAY 17·AD HOC NEWS▲
Argenx SE stock (NL0010832176): investor focus after latest Vyvgart updates and pipeline news
Argenx SE remains a key focus for investors due to recent updates concerning its autoimmune drug Vyvgart and broader pipeline. The company, specializing in antibody-based therapies for autoimmune and rare diseases, has seen Vyvgart become its main revenue driver, with ongoing efforts to expand its indications. Argenx continues to invest in R&D and market access, balancing its concentrated asset portfolio with significant growth potential in specialty-care markets.
APR 30·Yahoo Finance Singapore→
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
argenx (Euronext & Nasdaq: ARGX) announced it will host a conference call and audio webcast on Thursday, May 7, 2026, at 2:30 PM CET (8:30 AM ET) to discuss its first-quarter 2026 financial results and provide a business update. The webcast will be accessible through the Investors section of the argenx website, with a replay available for approximately one year. This event is for investors and the public to stay informed on the company's financial performance and business developments.
